Market Closed -
BME
09:05:18 31/05/2024 pm IST
5-day change
1st Jan Change
87.75
EUR
-0.28%
-4.10%
+45.76%
Sales 2024 *
82Cr
89Cr
7.39TCr
Sales 2025 *
91Cr
98Cr
8.19TCr
Capitalization
454.72Cr
493.46Cr
41TCr
Net income 2024 *
18Cr
19Cr
1.59TCr
Net income 2025 *
21Cr
23Cr
1.91TCr
EV / Sales 2024 *
5.5
x
Net cash position
2024
*
3.82Cr
4.15Cr
344.8Cr
Net cash position
2025
*
15Cr
16Cr
1.33TCr
EV / Sales 2025 *
4.85
x P/E ratio 2024 *
26.5
x
P/E ratio 2025 *
22
x
Employees
1,925
Yield 2024 *
1.28%
Yield 2025 *
1.52%
Free-Float
35.68%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
5 minutes 15 minutes 30 minutes 1 hour 1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024
08/05
CI
Spain's Rovi Obtains US FDA Approval for Marketing Risvan as Schizophrenia Treatment
02/04
MT
Rovi, Partners to Form Entity for Advanced Therapies R&D
12/03
MT
Rovi explores sale of unit that makes drugs for third parties
07/03
RE
Rovi Responds to Press Speculation Regarding Contract Development Business Deal
07/03
MT
Transcript : Laboratorios Farmaceuticos Rovi, S.A., 2023 Earnings Call, Feb 27, 2024
27/02
The Ibex-35 opts for caution as corporate results continue to trickle in.
27/02
RE
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023
26/02
CI
US FDA finds control lapses at Moderna manufacturing plant
16/12
RE
Italy, Spain stocks hit peaks after over 20% rally in 2023
30/11
RE
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023
08/11
CI
Transcript : Laboratorios Farmaceuticos Rovi, S.A., H1 2023 Earnings Call, Jul 26, 2023
26/23/26
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Half Year Ended June 30, 2023
26/23/26
CI
Tranche Update on Laboratorios Farmaceuticos Rovi, S.A.'s Equity Buyback Plan announced on November 3, 2021.
26/23/26
CI
Global markets live: Macy's, Salesforce, Dollar General, Nordstrom, Exxon...
01/23/01
More news
Cinco valores que se deben tener muy en cuenta por técnico este jueves
30/05
Cinco valores que se deben tener muy en cuenta por técnico este miércoles
22/05
LE OPINIONI DEGLI ANALISTI DEL GIORNO : Azimut, Banco Bpm, Credito Emiliano, Diasorin, Finecobank, Italgas, Reply, UniCredit, Hera, ...
15/05
Consultorio de análisis técnico : IAG, Rovi, Logista, Técnicas Reunidas, Berkeley, Audax, Acciona...
30/04
AVIS D'ANALYSTES DU JOUR : Hermès, Orange, Renault, TotalEnergies, Rémy Cointreau, Amundi, UBS...
29/04
More news 1 day -0.28%
1 week -4.10%
1 month +6.75%
3 months +16.46%
6 months +54.76%
Current year +45.76%
More quotes
Managers
Title Age Since
Chief Executive Officer
-
01/94/01
Director of Finance/CFO
-
01/00/01
Chief Tech/Sci/R&D Officer
-
-
Members of the board
Title Age Since
Director/Board Member
-
01/95/01
Director of Finance/CFO
-
01/00/01
Chief Executive Officer
-
01/94/01
More insiders
Date
Price
Change
Volume
31/24/31
87.75
-0.28%
120,959
30/24/30
88
-0.11%
39,694
29/24/29
88.1
-0.45%
30,823
28/24/28
88.5
-1.01%
64,767
27/24/27
89.4
-2.30%
79,410
Delayed Quote
BME, May 31, 2024 at 09:05 pm IST
More quotes
Laboratorios Farmaceuticos Rovi, S.A. specializes in the research, development, manufacturing and marketing of biological medications and specialty drugs. Net sales break down by family of products as follows:
- pharmaceutical products manufactured under contract (49%);
- prescription pharmaceuticals (45%): intended for preventing and treating venous thrombo-embolic disease, post-menopausal osteoporosis, muscle pain, tooth and mouth infections, angina, osteoarthritis, etc.;
- diagnostic products (6%): contrast products used in medical imaging with magnetic resonance, ultrasound, or X-rays. The group also offers hospital products and non-prescription pharmaceuticals.
Net sales break down by source of revenue between sales of products (50.6%), sales of services (49.3%) and sales of licenses (0.1%).
Net sales are distributed geographically as follows: Spain (33%), European Union (17.3%), OECD countries (45.9%) and other (3.8%).
More about the company
Last Close Price
87.75
EUR
Average target price
89.44
EUR
Spread / Average Target
+1.92%
Consensus
1st Jan change
Capi.
+45.76% 493.14Cr +40.73% 74TCr +32.83% 60TCr -6.30% 35TCr +15.15% 32TCr +4.05% 28TCr +15.00% 24TCr +9.78% 21TCr -5.52% 21TCr +6.17% 16TCr
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1